Increased sensitivity of IL2-dependent cultured T cells and enhancement of in vitro IL2 production by human lymphocytes treated with Bestatin.
Bestatin is an inhibitor of leucine aminopeptidase and aminopeptidase B which potentiates various immune functions, such as delayed hypersensitivity and antibody formation, and inhibits tumor cell growth in animal models. Our study focuses on the effect of Bestatin on interleukin 2 (IL2) sensitivity of IL2-dependent cultured T cells (CTC) and on IL2 production by human peripheral blood mononuclear cells (PBM). Bestatin (0.01 - 10 micrograms/ml) increases CTC 3H-TdR incorporation in the presence of suboptimal (low) concentrations of exogenous IL2. Bestatin alone has no mitogenic effect on CTC. This phenomenon is due to increased CTC IL2-receptors after treatment with Bestatin. Bestatin (1 - 10 micrograms/ml) also increases (1.4 - 21 fold) IL2 production by PHA-stimulated PBM. Bestatin therefore increases both IL2 sensitivity and IL2 production. This may explain the various immunopotentiating effects of Bestatin previously described.
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D006801:Humans; D007104:Immune Adherence Reaction; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000096:biosynthesis / Q000502:physiology*; D007930:Leucine / Q000031:analogs & derivatives* / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects*; D011971:Receptors, Immunologic / Q000187:drug effects; D015375:Receptors, Interleukin-2; D013601:T-Lymphocytes / Q000276:immunology*
D000276:Adjuvants, Immunologic; D007376:Interleukin-2; D011971:Receptors, Immunologic; D015375:Receptors, Interleukin-2; D007930:Leucine; C012211:ubenimex